Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study.

ABSTRACT: This phase 1, multi-center, nonrandomized, open-label, dose-escalation study consisted of Part A wherein merestinib 80 or 120 mg (40-mg tablets) was administered orally QD during a 28-day cycle to patients diagnosed with solid tumors and Part B wherein merestinib 80 mg (40-mg tablets) was administered orally QD, and cisplatin 25 mg/m²  + gemcitabine 1000 mg/m² administered IV on Day 1 and Day 8 of a 21-day cycle (for a maximum of eight cycles) to patients diagnosed with biliary tract carcinoma (BTC). Nineteen patients were screened and 18 patients were (Part A, n = 10; Part B, n = 8) enrolled in the trial and received treatment. All patients in Parts A and B were from Japan and were within an age range of 43-73 years, with an ECOG PS of 0.1. No dose-limiting toxicity

SUBMITTER: Doi T 

PROVIDER: S-EPMC8495281 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature